Immutep Ltd (ASX: IMM) Share Price and News

Dr. Howard is an executive manager, and entrepreneur. He was a pioneer in molecular parasitology and commercialisation of DNA Shuffling. He is an inventor of 9 patents and has over 140 scientific publications. He held positions at several research laboratories, including the National Institutes of Health in the USA where he gained tenure. In industry, he worked at Schering Ploughs DNAX Research Institute in Palo Alto, CA; was the President and Scientific Director of Affymax, Inc. and co-founder and CEO of Maxygen, Inc. He is Member of the Risk Committee.

Mr Meyers spent 18 years in health care investment banking, holding positions of increasing responsibility at Dillon, Read & Co., Credit Suisse First Boston LLC and, most recently, as Co Head of Global Health Care Investment Banking at Deutsche Bank Securities Inc. He is currently a NonExecutive Director of Yamo Pharmaceuticals LLC, a privately held, development stage company. In addition to his for profit, corporate board service, he is also the Chairman and President of The Thomas M. Brennan Memorial Foundation, Inc., and the Vice Chairman of East End Hospice, Inc. He is Chairman of the Risk Committee.

Mr Voigt has more than 25 years of experience in the financial and biotech industry, having joined the Immutep team in 2011 as the General Manager, European Operations based in Berlin, Germany. Having started his career at the Allianz Group working in pension insurances and funds, he moved to net.IPO AG, a publicly listed boutique investment bank in Frankfurt where he was focused on IPOs and venture capital investments. He then worked for a number of years as an investment manager for a midsize venture capital fund based in Berlin, specialising in healthcare. He also gained considerable operational experience while serving in different management roles with Revotar Biopharmaceuticals, Caprotec Bioanalytics and Medical Enzymes AG respectfully, where he handled several successful licensing transactions and financing rounds. He is also member of the investment committee of an Australian venture capital fund.

Professor Triebel was the scientific founder of Immutep S.A. (2001) and served as the Scientific and Medical Director at Immutep from 2004. Before starting Immutep S.A., he was Professor in Immunology at Paris University. While working at Institut Gustave Roussy (IGR), a large cancer centre in Paris, he discovered the LAG-3 gene in 1990 and continued working on this research program since then, identifying the functions and medical usefulness of this molecule. He headed a research group at IGR while also being involved in the biological follow up of cancer patients treated in Phase I/II immunotherapy trials. He was Director of an INSERM Unit from 1991 to 1996.

Ms Boyce has over 30 years of experience including capital raising, strategic collaborations, corporate governance and mergers & acquisitions. She is a partner in Piper Aldermans corporate team, and cochairs the firms Life Sciences & Healthcare focus group. She has strong focus on Life Sciences is reflected in her appointment as deputy chair of AusBiotechs AusMedtech Advisory Group, and as Chair of AusBiotechs Leadership Committee for NSW. He is Member of the Risk Committee.

-

-

-

-